Lipid-Based Self-Microemulsion of Niclosamide Achieved Enhanced Oral Delivery and Anti-Tumor Efficacy in Orthotopic Patient-Derived Xenograft of Hepatocellular Carcinoma in Mice
Yi Liu,David Guerrero,David Lechuga-Ballesteros,Mingdian Tan,Faiz Ahmad,Bilal Aleiwi,Edmund Ellsworth,Bin Chen,Mei-Sze Chua,Samuel So
DOI: https://doi.org/10.2147/ijn.s442143
IF: 7.033
2024-03-14
International Journal of Nanomedicine
Abstract:Yi Liu, 1 David Quintanar Guerrero, 2 David Lechuga-Ballesteros, 3 Mingdian Tan, 1 Faiz Ahmad, 1 Bilal Aleiwi, 4 Edmund Lee Ellsworth, 4 Bin Chen, 4 Mei-Sze Chua, 1 Samuel So 1 1 Department of Surgery, School of Medicine, Stanford University, Stanford, CA, USA; 2 Laboratorio de Investigación y Posgrado en Tecnologías Farmacéuticas, Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli, CP, 54745, Mexico; 3 AstraZeneca Pharmaceuticals, Ltd. 4222 Emperor Boulevard, Durham, NC, USA; 4 Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI, USA Correspondence: Mei-Sze Chua, Email Introduction: We previously identified niclosamide as a promising repurposed drug candidate for hepatocellular carcinoma (HCC) treatment. However, it is poorly water soluble, limiting its tissue bioavailability and clinical application. To overcome these challenges, we developed an orally bioavailable self-microemulsifying drug delivery system encapsulating niclosamide (Nic-SMEDDS). Methods: Nic-SMEDDS was synthesized and characterized for its physicochemical properties, in vivo pharmacokinetics and absorption mechanisms, and in vivo therapeutic efficacy in an orthotopic patient-derived xenograft (PDX)-HCC mouse model. Niclosamide ethanolamine salt (NEN), with superior water solubility, was used as a positive control. Results: Nic-SMEDDS (5.6% drug load) displayed favorable physicochemical properties and drug release profiles in vitro. In vivo, Nic-SMEDDS displayed prolonged retention time and plasma release profile compared to niclosamide or NEN. Oral administration of Nic-SMEDDS to non-tumor bearing mice improved niclosamide bioavailability and C max by 4.1- and 1.8-fold, respectively, compared to oral niclosamide. Cycloheximide pre-treatment blocked niclosamide absorption from orally administered Nic-SMEDDS, suggesting that its absorption was facilitated through the chylomicron pathway. Nic-SMEDDS (100 mg/kg, bid) showed greater anti-tumor efficacy compared to NEN (200 mg/kg, qd); this correlated with higher levels ( p < 0.01) of niclosamide, increased caspase-3, and decreased Ki-67 in the harvested PDX tissues when Nic-SMEDDS was given. Biochemical analysis at the treatment end-point indicated that Nic-SMEDDS elevated lipid levels in treated mice. Conclusion: We successfully developed an orally bioavailable formulation of niclosamide, which significantly enhanced oral bioavailability and anti-tumor efficacy in an HCC PDX mouse model. Our data support its clinical translation for the treatment of solid tumors. Keywords: niclosamide, self-microemulsifying drug delivery system, SMEDDS, oral bioavailability, drug repurposing, hepatocellular carcinoma We previously used a bioinformatics approach to identify drugs (that have been approved by the Food and Drug Administration (FDA)), that can reverse the gene expression profiles of HCC cells to that of normal hepatocytes. Our efforts revealed niclosamide as top repurposing drug candidate for HCC treatment. 1 Niclosamide is an FDA-approved oral antiparasitic drug for treating tapeworm infection in humans. 2 In this capacity, it acts primarily by uncoupling oxidative phosphorylation in the mitochondria to impede metabolism. 3 Recent evidence indicates that niclosamide has a broad spectrum of action, including the inhibition of multiple signaling pathways that are critical in cancer cells. 4 Although in vitro data suggest encouraging anti-tumor effects in HCC, 1 colon cancer, 5 and prostate cancer, 6 subsequent animal studies and clinical trials in these cancer types have not been unsuccessful (NCT02687009; NCT03123978; NCT02807805; NCT02519582; NCT02532114). This is attributed to poor systemic exposure due to low water solubility and, consequently low bioavailability, preventing niclosamide from reaching the solid tumor sites. In order to achieve sufficiently high plasma concentrations required for anti-cancer effects, higher than approved doses of niclosamide are needed, which may lead to dose-limiting toxicities. 6,7 Although niclosamide failed to achieve significant anti-HCC efficacy in mouse models, its more water-soluble ethanolamine salt, niclosamide ethanolamine (NEN), significantly reduced the growth of an orthotopic HCC patient-derived xenograft (PDX) in mice. 1 This provided evidence that enhancing the water solubility of niclosamide is a practical approach to enhancing its anti-tumor efficacy in HCC. However, NEN is not FDA-approved for human use, prompting us to deve -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology